Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xanthohumol is a prenylated chalcone and the principal flavonoid found in the female flowers (cones) of the hop plant (*Humulus lupulus* L.), which is also used in beer production[1][2][5]. It exhibits a wide range of biological activities, including anti-inflammatory, antioxidant, antimicrobial, antineoplastic (anticancer), anti-aging, and metabolic effects demonstrated in cell culture and animal models[1][3][5]. Mechanistically, xanthohumol has been shown to inhibit valosin-containing protein (VCP), impairing autophagosome maturation; it can induce protective detoxification enzymes via activation of the nuclear factor erythroid 2–related factor 2 pathway; and it may modulate estrogenic pathways through its metabolites[6][5]. Research into its clinical applications includes potential roles in cancer prevention/treatment and metabolic syndrome. However, its poor solubility and bioavailability have prompted development of novel delivery systems such as nanoparticles or polymer-based carriers to enhance therapeutic efficacy[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xanthohumol.